Efficacy of Sovaldi and Rabavirin Combine Therapy in Chronic Hepatitis C Patients in District Peshawar, Khyber Pakhtunkhwa

Abstract

The efficacy of Sovaldi and Rabivirin Combine therapy in chronic Hepatitis C patients were determined and also find out factors such as gender and age that can influence response to antiviral therapy. A quasi–experimental Study were carried out in Gastroenterology and Pathology department, Hayatabad Medical Complex (HMC), Peshawar, from February 2016 to July 2016. Patients were given 400 mg oral Sovaldi and 800- 1200 mg oral Rabavirin two doses in a day for a period of 180 days. At the end of treatment the response of the combine therapy was depicted from the negative RNA of HCV by PCR after 24 weeks of treatment. Factors like age, gender and serum ALT were examined of the patients and determined the relations of these factors with the efficacy of Sovaldi combine with Ribavirin. Total 113 patients age up to 60 years, were given combine treatment that full filled the inclusion criteria. Sovaldi and Ribavirin in combination therapy showed better response compare to other drugs. Females and young age patients were favorable responders.